Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript Summary
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript Summary
The success of the Co-Dx PCR testing platform is contingent on receiving the necessary regulatory approvals from the U.S. FDA.The following is a summary of the Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript:
以下是co-diagnostics,Inc.(CODX)2024年第三季度業績會成績單摘要:
Business Progress:
業務進展:
Co-Diagnostics is currently seeking regulatory approval and marketing authorization for its forthcoming Co-Dx PCR testing platform.
Co-Diagnostics目前正在尋求其即將推出的Co-Dx PCR檢測平台的監管批准和營銷授權。
Opportunities:
機會：
The Co-Dx PCR testing platform represents a significant opportunity for market expansion and product innovation in the diagnostic testing market once regulatory approvals are obtained.
一旦獲得監管批准，Co-Dx PCR檢測平台將爲市場擴張和產品創新提供重要機遇。
Risks:
風險：
The success of the Co-Dx PCR testing platform is contingent on receiving the necessary regulatory approvals from the U.S. FDA.
Co-Dx PCR檢測平台的成功取決於從美國FDA獲得必要的監管批准。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
